EDMONTON , Aug. 22, 2018 /CNW/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) announced it received Health Canada authorization to produce cannabis softgel capsules at its Aurora Vie facility in Pointe-Claire, Québec. Aurora will begin production of softgel capsules immediately, in partnership with Capcium Inc. (“Capcium”), the Montreal -based manufacturer that specializes in high-volume softgel encapsulation. Aurora holds a 19.99% ownership stake in Capcium and is Aurora’s exclusive manufacturer of cannabis softgel products in North America .
Aurora announced the launch of a line of hardshell, vegan, precision-dose, medical cannabis capsules. Balanced with a blend of equal concentrations of THC and CBD (3mg/capsule of each cannabinoid), the product has no taste and offers reliable, long-lasting and consistent effects. The company states that the CanniMed Capsules are a game-changer for patients and healthcare professionals who have been seeking alternative delivery systems for medical cannabis.
“Aurora continues to deliver on its strategy to build a robust portfolio of higher-margin products, and we are proud of the scientific innovation and dedication to patient well-being reflected by the launch of our cannabis capsules that offer a discreet and smoke free method of consumption for patients,” said Terry Booth , CEO of Aurora. “While many people continue to use dried buds for medical symptom relief, there is growing global demand for alternative drug delivery technologies. Through CanniMed and our partnership with Capcium, we are well-positioned to lead in this segment of the Cannabis market. We look forward to reporting on future innovations from the combined product development teams at Aurora, CanniMed, CTT pharmaceutical, Capcium and MedReleaf.”